Several presentations at the ASCO Breast Cancer Symposium addressed important questions in triple-negative breast cancer: are there promising new treatment approaches for these patients and how can we identify which patients are high risk? More »
The FDA approved a dissolvable form of everolimus (Afinitor Disperz) for the treatment of children with subependymal giant cell astrocytoma (SEGA) that cannot be treated with surgery. More »
Lung cancer remains the number one cancer killer in both men and women, with more deaths attributable to lung cancer than breast, prostate, and colorectal cancers combined.[1] More »
Lhermitte-Duclos disease is a rare, slow-growing, benign lesion of the cerebellum and is considered a hamartomatous tumor of the cerebellar cortex. More »
The FDA approved the mTOR inhibitor everolimus (Afinitor) last week for use in postmenopausal women with HER2-negative, hormone-receptor-positive advanced breast cancer patients. More »
The new diagnostic test to detect KRAS gene mutations, will facilitate speedier assessment of the KRAS mutation status of a patient’s tumor to allow for an earlier treatment decision to use cetuximab or to go on with another treatment. More »
CancerNetwork speaks with Dr. Sara Hurvitz, director of the breast cancer program at the University of California in Los Angeles. Dr. Hurvitz is actively involved in translational phase I/II breast cancer clinical trials as well as in research to better define distinct types of breast tumors to better design novel targeted therapies. More »
Scientists in Germany have potentially found a way to indirectly target the MYC oncogene—an elusive cancer therapy target to date, discovering that cancer cells with upregulated levels of MYC are dependent on AMPK-related kinase 5 to stay alive. Inhibition of ARK5 causes these MYC-dependent cells to die. More »
A combination of cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, and temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor, showed evidence of activity in refractory Ewing’s sarcoma tumors as well as small-round-cell tumors in a phase I multicenter clinical study. More »
Endocrine-therapy resistant HER2-negative breast cancer is the most common cause of breast cancer death. The basis for this resistance is heavily studied to identify new ways to treat these patients. More »
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril Marion K. Jenkins, May 21, 2013 Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Three Areas to Reduce Costs at Your Medical Practice Greg Mertz, May 19, 2013 By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog Michael Woo-Ming, MD, May 18, 2013 Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
